Loss of 15-hydroxyprostaglandin dehydrogenase indicates a tumor suppressor role in pituitary adenomas

Oncology Reports
Ji-Wei BaiYa-Zhuo Zhang

Abstract

15-hydroxyprostaglandin dehydrogenase (15-PGDH) may function as a tumor suppressor that antagonizes the action of the cyclooxygenase-2 (COX-2) oncogene in several types of tumors. However, it is unknown if it has a role in the pituitary. Recently, our group found that 15-PGDH expression was low in prolactin (PRL) secreting adenomas (prolactinomas) and growth hormone (GH) secreting adenomas (GHomas) using fiber-optic BeadArray technology. In this study, we examined the relative expression of 15-PGDH and COX-2 mRNA in clinical specimens and examined the effects of 15-PGDH on GH3 rat pituitary tumor cell proliferation, apoptosis and hormone secretion. 15-PGDH expression was lower and COX-2 expression was higher in prolactinomas and GHomas compared with normal controls. Overexpressed 15-PGDH inhibited tumor cell proliferation and induced apoptosis. It had a significant suppressive effect on mRNA levels and on the secretion of PRL and GH in GH3 cells. The inhibition of cell proliferation was accompanied by the decreased expression of cox-2, matrix metalloproteinase-9 (MMP-9) and B cell leukemia/lymphoma-2 (Bcl-2). These data are suggestive of a previously unrecognized pathway in pituitary tumorigenesis, and this novel observation ma...Continue Reading

References

Aug 28, 1995·Brain Research. Developmental Brain Research·R Cañete SolerR J Muschel
Jan 1, 1994·Endocrinology·G R FrankS Handwerger
Jan 14, 2000·The Journal of Clinical Endocrinology and Metabolism·M Páez PeredaG K Stalla
Aug 18, 2000·The Journal of Clinical Endocrinology and Metabolism·H E TurnerJ A Wass
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
May 27, 2003·Cancer·Sergio VidalRicardo V Lloyd
May 19, 2005·Cancer Research·Dimitri LodyginHeiko Hermeking
Mar 15, 2006·Current Pharmaceutical Design·H-H TaiY Ding
Aug 2, 2006·Proceedings of the National Academy of Sciences of the United States of America·Seung-Jae MyungSanford D Markowitz
Aug 4, 2006·Cancer Research·Ido WolfH Phillip Koeffler
May 8, 2007·Prostaglandins & Other Lipid Mediators·Hsin-Hsiung TaiYunfei Ding
Jan 5, 2008·Carcinogenesis·Zhenxiong LiuDaiming Fan
Aug 9, 2008·Histochemistry and Cell Biology·Robert Y OsamuraAkira Teramoto
Apr 30, 2009·Annual Review of Pathology·Sylvia L Asa, Shereen Ezzat
Nov 6, 2009·Molecular Cancer Therapeutics·Lyudmila N KaliberovaSergey A Kaliberov
Jan 23, 2010·The American Journal of Pathology·Stephanie Tseng-RogenskiMonica Liebert
Aug 2, 2011·Molecular and Cellular Endocrinology·María Eugenia MatzkinMónica Beatriz Frungieri
Oct 25, 2011·Cancer Metastasis Reviews·Hsin-Hsiung Tai

❮ Previous
Next ❯

Citations

Aug 16, 2013·Journal of Lipid Research·Nathaniel W SnyderIan A Blair

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis